Screener
ADMA Biologics ADMA Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
FAQ
- What is ADMA Biologics's accounts receivable?
- ADMA Biologics (ADMA) reported accounts receivable of $138.23M in Q2 2026.
- How has ADMA Biologics's accounts receivable changed year-over-year?
- ADMA Biologics's accounts receivable increased by 26.0% year-over-year, from $109.73M to $138.23M.
- What is the long-term trend for ADMA Biologics's accounts receivable?
- Over 5 years (2020 to 2025), ADMA Biologics's accounts receivable has grown at a 64.3% compound annual growth rate (CAGR), from $13.24M to $158.43M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about ADMA Biologics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude